29 June 2020

Amedeo Smart

Independent Medical Education


Subscriber: th..@boehringer-ingelheim.com

HIV Infection

29 June 2020 | n=55

  1. Adachi E, Saito M, Ikeuchi K, Hoshina T, et al.
    Cases of coronavirus disease-2019 in HIV-infected transgender women.
    AIDS 2020;34:1435-1436.

  2. Proietti I, Skroza N, Michelini S, Mambrin A, et al.
    Efficacy of nivolumab in HIV patient with melanoma brain metastases.
    AIDS 2020;34:1433-1435.

  3. Berzkalns AE, Barbee LA, Dombrowski JC, Golden MR, et al.
    Low HIV incidence among women following sexually transmitted infection does not support national pre-exposure prophylaxis recommendations.
    AIDS 2020;34:1429-1431.

  4. Alufandika M, Lawrence DS, Boyer-Chammard T, Kanyama C, et al.
    A pragmatic approach to managing antiretroviral therapy-experienced patients diagnosed with HIV-associated cryptococcal meningitis: impact of antiretroviral therapy adherence and duration.
    AIDS 2020;34:1425-1428.

  5. Sampaio JDA, Jacome-Santos H, Aires AV, Pinheiro JJV, et al.
    Orofacial outcomes in adolescents with perinatally infected HIV in antiretroviral therapy.
    AIDS 2020;34:1417-1423.

  6. Calvert C, Marston M, Slaymaker E, Crampin AC, et al.
    Direct maternal deaths attributable to HIV in the era of antiretroviral therapy: evidence from three population-based HIV cohorts with verbal autopsy.
    AIDS 2020;34:1397-1405.

  7. Liang J, Nosova E, Reddon H, Nolan S, et al.
    Longitudinal patterns of illicit drug use, antiretroviral therapy exposure and plasma HIV-1 RNA viral load among HIV-positive people who use illicit drugs.
    AIDS 2020;34:1389-1396.

  8. Lam E, Hites M, Cantinieaux B, Van Laethem Y, et al.
    Malaria in HIV-infected patients in a nonendemic setting.
    AIDS 2020;34:1359-1365.

  9. Hosseini-Hooshyar S, Martinello M, Yee J, Read P, et al.
    Low hepatitis C virus reinfection rate despite ongoing risk following universal access to direct-acting antiviral therapy among people living with HIV.
    AIDS 2020;34:1347-1358.

  10. Patel MR, Mushavi A, Balachandra S, Shambira G, et al.
    HIV-exposed uninfected infant morbidity and mortality within a nationally representative prospective cohort of mother-infant pairs in Zimbabwe.
    AIDS 2020;34:1339-1346.

  11. Mwimanzi F, Ngare I, Toyoda M, Mori M, et al.
    An HIV-1 Nef genotype that diminishes immune control mediated by protective human leucocyte antigen alleles.
    AIDS 2020;34:1325-1330.

  12. Mastro TD, Akolo C, Shoptaw S.
    Managing amphetamine use is critical to achieving HIV control.
    AIDS 2020.

  13. Stankevitz K, Grant H, Lloyd J, Gomez GB, et al.
    Oral pre-exposure prophylaxis (PrEP) continuation, measurement, and reporting: a systematic review and meta-analysis.
    AIDS 2020.

  14. Gojanovich GS, Jacobson D, Jao J, Russell J, et al.
    Mitochondrial Dysfunction and Insulin Resistance in Pubertal Youth Living with Perinatally-acquired HIV.
    AIDS Res Hum Retroviruses 2020.

  15. Wang H, Chang Y, Cui ZZ, Liu ZJ, et al.
    Admission CRP-to-albumin ratio predicts the 180-day mortality of acquired immunodeficiency syndrome-related pneumocystis pneumonia.
    AIDS Res Hum Retroviruses 2020.

  16. Del Amo J, Polo R, Moreno S, Diaz A, et al.
    Incidence and Severity of COVID-19 in HIV-Positive Persons Receiving Antiretroviral Therapy: A Cohort Study.
    Ann Intern Med 2020.

  17. Bartlett AW, Sudjaritruk T, Mohamed TJ, Anugulruengkitt S, et al.
    Identification, management and outcomes of combination antiretroviral treatment failure in adolescents with perinatal HIV infection in Asia.
    Clin Infect Dis 2020.

  18. Wu D, Zhou Y, Yang N, Huang S, et al.
    Social media-based secondary distribution of HIV/syphilis self-testing among Chinese men who have sex with men.
    Clin Infect Dis 2020.

  19. Lindsey JC, Jacobson DL, Spiegel H, Gordon CM, et al.
    Safety and efficacy of 48 and 96 weeks of alendronate in children and adolescents with perinatal HIV infection and low bone mineral density for age.
    Clin Infect Dis 2020.

  20. Jo Y, Shrestha S, Gomes I, Marks S, et al.
    Model-Based Cost-Effectiveness of State-level Latent Tuberculosis Interventions in California, Florida, New York and Texas.
    Clin Infect Dis 2020.

  21. Zhao R, Tao Y, Zhang L.
    Can social media-based self-testing be a new paradigm for HIV testing in China?
    Clin Infect Dis 2020.

  22. Kersh EN, Workowski KA.
    Evidence Review for Centers for Disease Control and Prevention Guidance Development on Laboratory Testing to Detect Treponema pallidum Infection (Syphilis).
    Clin Infect Dis 2020;71:S1-S3.

  23. Park IU, Tran A, Pereira L, Fakile Y, et al.
    Sensitivity and Specificity of Treponemal-specific Tests for the Diagnosis of Syphilis.
    Clin Infect Dis 2020;71:S13-S20.

  24. Ortiz DA, Shukla MR, Loeffelholz MJ.
    The Traditional or Reverse Algorithm for Diagnosis of Syphilis: Pros and Cons.
    Clin Infect Dis 2020;71:S43-S51.

  25. Wu Z, McGoogan JM, Detels R.
    The enigma of the HIV epidemic in China.
    Clin Infect Dis 2020.

  26. Stalter RM, Baeten JM, Donnell D, Spinelli MA, et al.
    Urine Tenofovir Levels Measured by a Novel Immunoassay Predict HIV Protection.
    Clin Infect Dis 2020.

  27. Jacobs P, Feaster DJ, Pan Y, Gooden L, et al.
    Initiation of Antiretroviral Therapy in the Hospital is Associated with Linkage to HIV Care for Persons Living with HIV and Substance Use.
    Clin Infect Dis 2020.

  28. LaCourse SM, Richardson BA, Kinuthia J, Warr AJ, et al.
    A randomized controlled trial of isoniazid to prevent Mycobacterium tuberculosis infection in Kenyan HIV-exposed uninfected infants.
    Clin Infect Dis 2020.

  29. Thu NTM, Chan JFW, Ly VT, Ngo HT, et al.
    Superiority of a novel Mp1p antigen detection enzyme immunoassay compared to standard BACTEC blood culture in the diagnosis of talaromycosis.
    Clin Infect Dis 2020.

  30. Theron G, Brummel S, Fairlie L, Pinilla M, et al.
    Pregnancy outcomes of women conceiving on antiretroviral therapy (ART) compared to those commenced on ART during pregnancy.
    Clin Infect Dis 2020.

  31. Maurice J, Lemoine M.
    Are separate clinical trials still required in NASH for patients with and without HIV?
    Clin Infect Dis 2020.

  32. Puyat JH, Shulha HP, Balshaw R, Campbell JR, et al.
    How well does TSTin3D predict risk of active tuberculosis in the Canadian immigrant population? An External Validation Study.
    Clin Infect Dis 2020.

  33. Papasavvas E, Azzoni L, Ross BN, Fair M, et al.
    Intact HIV reservoir estimated by the intact proviral DNA assay correlates with levels of total and integrated DNA in the blood during suppressive antiretroviral therapy.
    Clin Infect Dis 2020.

  34. Manion M, Lynn N, Pei L, Hammoud DA, et al.
    To Induce IRIS or Suppress It: The spectrum of Mycobacterium genavense in the antiretroviral era.
    Clin Infect Dis 2020.

  35. Boettiger DC, Kerr S, Chattranukulchai P, Siwamogsatham S, et al.
    Re-classification of statin indication among people living with HIV using coronary artery calcium scoring.
    J Acquir Immune Defic Syndr 2020.

  36. Morris SE, Dziobek-Garrett L, Strehlau R, Schroter J, et al.
    Quantifying the dynamics of HIV decline in perinatally-infected neonates on antiretroviral therapy.
    J Acquir Immune Defic Syndr 2020.

  37. Hu Y, Ma J, Huang H, Vermund SH, et al.
    Coinfection with HIV and SARS-CoV-2 in Wuhan, China: A 12-person case series.
    J Acquir Immune Defic Syndr 2020.

  38. Karmen-Tuohy S, Carlucci PM, Zervou FN, Zacharioudakis IM, et al.
    Outcomes among HIV-positive patients hospitalized with COVID-19.
    J Acquir Immune Defic Syndr 2020.

  39. Grover S, Mehta P, Wang Q, Bhatia R, et al.
    Association between CD4 count and chemoradiation therapy outcomes among cervical cancer patients with HIV.
    J Acquir Immune Defic Syndr 2020.

  40. Calza L, Bon I, Borderi M, Colangeli V, et al.
    NO SIGNIFICANT EFFECT OF COVID-19 ON IMMUNOLOGICAL AND VIROLOGICAL PARAMETERS IN PATIENTS WITH HIV-1 INFECTION.
    J Acquir Immune Defic Syndr 2020.

  41. Weiser JK, Vu QM, Dasgupta S, Nelson NP, et al.
    Estimated Additional Number of Adults in HIV Care Who have an Indication for Hepatitis A Vaccination Following 2020 US Guideline Update.
    J Acquir Immune Defic Syndr 2020.

  42. Tarleton J, Chen BA, Meyn LA, Hendrix CW, et al.
    Pharmacokinetic and pharmacodynamic impacts of depot medroxyprogesterone acetate use on HIV pre-exposure prophylaxis in women.
    J Acquir Immune Defic Syndr 2020.

  43. Saloner R, Cherner M, Iudicello JE, Heaton RK, et al.
    Cerebrospinal Fluid Norepinephrine and Neurocognition in HIV and Methamphetamine Dependence.
    J Acquir Immune Defic Syndr 2020.

  44. Tuyishime M, Garrido C, Jha S, Moeser M, et al.
    Improved Killing of HIV-infected Cells Using Three Neutralizing and Non-neutralizing Antibodies.
    J Clin Invest 2020.

  45. Yeh YJ, Jenike KM, Calvi RM, Chiarella J, et al.
    Filgotinib suppresses HIV-1-driven gene transcription by inhibiting HIV-1 splicing and T cell activation.
    J Clin Invest 2020.

  46. Byakwaga H, Barbachano-Guerrero A, Wang D, McAllister S, et al.
    Immunoglobulin E (IgE) Levels are associated with Kaposi's Sarcoma in HIV-Infected African Adults.
    J Infect Dis 2020.

  47. Wagner AD, Kinuthia J, Dettinger J, Mwongeli N, et al.
    Challenges of discrepant HIV tests in pregnant women in the PrEP era - to treat or not to treat?
    J Infect Dis 2020.

  48. Knudsen AD, Ronit A, Kristensen T, Thomsen MT, et al.
    Pulmonary arterial enlargement in well-treated persons with HIV.
    J Infect Dis 2020.

  49. Ruan L, Zhang Y, Luo Y, Yu X, et al.
    Clinical features and outcomes of four HIV patients with COVID-19 in Wuhan, China.
    J Med Virol 2020.

  50. Ko K, Nagashima S, Yamamoto C, Takahashi K, et al.
    18 Years Follow-up Cohort Study on Hepatitis B and C Virus Infections Related Long Term Prognosis among Hemodialysis Patients in Hiroshima.
    J Med Virol 2020.

  51. Wang H, Liu Y, Huan C, Yang J, et al.
    Long noncoding RNA NKILA regulates HIV-1 replication and latency through repressing NF-kB signaling.
    J Virol 2020.

  52. Powell RL, Weiss S, Fox A, Liu X, et al.
    An HIV vaccine targeting the V2 region of Envelope induces a highly durable polyfunctional Fc-mediated antibody response in rhesus macaques.
    J Virol 2020.

  53. Rawat P, Hon S, Teodorof-Diedrich C, Spector SA, et al.
    Trehalose Inhibits Human Immunodeficiency Virus type-1 Infection in Primary Human Macrophages and CD4(+) T lymphocytes through Two Distinct Mechanisms.
    J Virol 2020.

  54. Chaisson RE.
    Empirical Antituberculosis Therapy in Advanced HIV Disease - Too Much, Too Late.
    N Engl J Med 2020;382:2459-2460.

  55. Blanc FX, Badje AD, Bonnet M, Gabillard D, et al.
    Systematic or Test-Guided Treatment for Tuberculosis in HIV-Infected Adults.
    N Engl J Med 2020;382:2397-2410.


Display articles in


Amedeo HIV Infection

Data Origin

You selected the following journals for your Amedeo HIV Infection newsletter:

AIDS, AIDS Res Hum Retroviruses, Ann Intern Med, BMJ, Clin Infect Dis, J Acquir Immune Defic Syndr, J Clin Immunol, J Clin Invest, J Infect Dis, J Med Virol, J Virol, JAMA, Lancet, N Engl J Med, Nat Med, Pediatr Infect Dis J, Science, Virology.

To modify the journal selection, please open your Newsletter Management Page. If you don't remember the URL, please submit the email address of your Amedeo subscription.

Your email:



Amedeo HIV Infection

Five-Week Literature

13 July 2020

06 July 2020

29 June 2020

22 June 2020

15 June 2020


29 June 2020

Multidisciplinary Journal Club

  1. Burn J, Sheth H, Elliott F, Reed L, et al.
    Cancer prevention with aspirin in hereditary colorectal cancer (Lynch syndrome), 10-year follow-up and registry-based 20-year data in the CAPP2 study: a double-blind, randomised, placebo-controlled trial.
    Lancet. 2020;395:1855-1863.

  2. Irwin DJ, Felder J, Coffey CS, Caspell-Garcia C, et al.
    Evolution of Alzheimer's Disease Cerebrospinal Fluid Biomarkers in Early Parkinson's Disease.
    Ann Neurol. 2020 Jun 16. doi: 10.1002/ana.25811.

  3. Gutzmer R, Stroyakovskiy D, Gogas H, Robert C, et al.
    Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAF(V600) mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial
    Lancet. 2020;395:1835-1844.

Every week, Amedeo's Multidisciplinary Journal Club (MJC) presents a selection of outstanding articles. Take a look beyond the horizon.


Free Medical Abstracts
Privacy Policy
Sponsors
Share
About

© Amedeo 1997-2016